BioXcel Therapeutics
BTAI
20 hedge funds and large institutions have $34.2M invested in BioXcel Therapeutics in 2018 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 8 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.39% less ownership
Funds ownership: 1.88% → 1.49% (-0.39%)
9% less funds holding
Funds holding: 22 → 20 (-2)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
29% less capital invested
Capital invested by funds: $47.9M → $34.2M (-$13.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
Artemis Investment Management
Edinburgh,
United Kingdom
|
+$268K |
| 2 |
BlackRock
New York
|
+$143K |
| 3 |
Millennium Management
New York
|
+$142K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$60.6K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$55.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$6.33M |
| 2 |
AC
Ascend Capital
Orinda,
California
|
-$2.05M |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$922K |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$444K |
| 5 |
California Public Employees Retirement System
Sacramento,
California
|
-$285K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CCA
26
Catalyst Capital Advisors
Huntington,
New York
| – | -$5K | -28 | Closed |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| – | -$1K | -6 | Closed |
|
28
Bank of Montreal
Toronto,
Ontario, Canada
| – | +$153 | +1 | New |
|
BTAI Hedge Fund Activity: Q2 2018 in Review
20 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q2 2018, worth a combined $34.2M — down 29% from $47.9M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of BTAI and 6 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 5 added.
The largest buyer was Artemis Investment Management, adding an estimated $268K. The largest seller was Barclays, exiting entirely with an estimated $6.33M sold.
- 20 institutional investors held BioXcel Therapeutics (BTAI) as of Q2 2018, down from 22 in Q1 2018.
- Funds reported $34.2M of BioXcel Therapeutics stock for Q2 2018, down 29% quarter-over-quarter.
- 6 funds opened new BioXcel Therapeutics positions in Q2 2018 and 8 closed out, a net change of -2 holders.
- The largest BioXcel Therapeutics buyer in Q2 2018 was Artemis Investment Management, an estimated $268K added.
- The largest BioXcel Therapeutics seller in Q2 2018 was Barclays, an estimated $6.33M sold.
Based on aggregated 13F filings for Q2 2018.